Katrin Hruska's guest appearances

Katrin Hruska

Coda Change

Framgångspodden

Akutläkarpodden

Jordan Peterson

Joe Dispenza

Gary Vaynerchuk

Jordan Belfort

Robin Sharma

James Tooley

Chris Fox

Simon Sinek

Chris Nickson

Anders Ericsson

Babba Rivera

Tommy Palm

John Hinds

Paul Marik

Zack Shinar

OwlTail

Akutläkaren Katrin Hruska gästar detta specialavsnitt i Framgångspodden och lär oss allt vi behöver veta om corona-viruset, COVID-19. Vi går igenom allt från virusets ursprung, hur det smittar till hur man som privatperson egentligen bör agera nu. Dessutom fick jag in massor av lyssnarfrågor från som vi betar oss igenom. Vad kan man förvänta sig härnäst i samhället? Hur många kommer att dö? Fungerar ansiktsmasker? Vad har Sverige för strategi? Varför bryr sig alla om coronan men ingen om influensan? Detta och mycket, mycket mer i detta matiga avsnitt som alla bör ta del av! Tusen tack för att du lyssnar! Beställ Framgångsboken: bit.ly/2DK4cvy  Alexander Pärleros Instagram: www.instagram.com/alexanderparleros  Bästa tipsen från avsnittet i Nyhetsbrevet: www.framgangspodden.se Hosted on Acast. See acast.com/privacy for more information.

Akutläkaren Katrin Hruska gästar detta specialavsnitt i Framgångspodden och lär oss allt vi behöver veta om corona-viruset, COVID-19. Vi går igenom allt från virusets ursprung, hur det smittar till hur man som privatperson egentligen bör agera nu. Dessutom fick jag in massor av lyssnarfrågor från som vi betar oss igenom. Vad kan man förvänta sig härnäst i samhället? Hur många kommer att dö? Fungerar ansiktsmasker? Vad har Sverige för strategi? Varför bryr sig alla om coronan men ingen om influensan? Detta och mycket, mycket mer i detta matiga avsnitt som alla bör ta del av! Tusen tack för att du lyssnar! Beställ Framgångsboken: <a href="http://bit.ly/2DK4cvy" rel="nofollow" target="_blank">bit.ly/2DK4cvy</a> Alexander Pärleros Instagram: <a href="http://www.instagram.com/alexanderparleros" rel="nofollow" target="_blank">www.instagram.com/alexanderparleros</a> Bästa tipsen från avsnittet i Nyhetsbrevet: <a href="http://www.framgangspodden.se" rel="nofollow" target="_blank">www.framgangspodden.se</a> Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

364. Allt om Corona med akutläkaren Katrin Hruska, Original

364. Allt om Corona med akutläkaren Katrin Hruska, Short

Katrin Hruska discusses the usefulness of biomarkers in Emergency Medicine. All biomarkers are awesome predictors of badness. Elevated hS-troponins after non-cardiac surgery or an acute exacerbation of COPD are associated with increased mortality. In seemingly healthy people, elevated D-dimer levels are associated with increased mortality. Similarly, NT-proBNP levels predict mortality in patients with end-stage renal disease. A biomarker, in its broadest sense, is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” (NIH Biomarkers Definitions Working group, 2001). This definition includes everything from laboratory tests to blood pressure measurements or an ultrasound scan. The clinical assessment in the Emergency Department is based on the subjective history of the patient and all available biomarkers (and their change over time). If we assume that biomarkers are objectively measured, there is an overestimation of their individual importance. As Katrin explains, over testing and over diagnosis have serious consequences. Not only for patients but also for the healthcare system. In a clinical context the ease of getting a laboratory test leads to a lower threshold for testing. This increases testing without affecting relevant clinical endpoints. Also, when a biomarker becomes part of the standardised workup for a certain symptom, primary care centres and emergency telephone services will refer patients to the Emergency Department for testing, even when the pretest probability is low. Katrin contends this bias is not an inherent problem of biomarkers themselves, but of the decision-making process of clinicians. The human brain fears uncertainty. Anything that adds to the feeling of knowing is rewarding, which is the most probable explanation of over testing in settings where medico-legal risks for the clinicians are low. There is an ever-increasing number of patients seeking to rule out serious conditions by relying on biomarker testing to provide certainty. Finally, for more like this, head to our podcast page. #CodaPodcast

Katrin Hruska discusses the usefulness of biomarkers in Emergency Medicine. All biomarkers are awesome predictors of badness. Elevated hS-troponins after non-cardiac surgery or an acute exacerbation of COPD are associated with increased mortality. In seemingly healthy people, elevated D-dimer levels are associated with increased mortality. Similarly, NT-proBNP levels predict mortality in patients with end-stage renal disease. A biomarker, in its broadest sense, is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” (NIH Biomarkers Definitions Working group, 2001). This definition includes everything from laboratory tests to blood pressure measurements or an ultrasound scan. The clinical assessment in the Emergency Department is based on the subjective history of the patient and all available biomarkers (and their change over time). If we assume that biomarkers are objectively measured, there is an overestimation of their individual importance. As Katrin explains, over testing and over diagnosis have serious consequences. Not only for patients but also for the healthcare system. In a clinical context the ease of getting a laboratory test leads to a lower threshold for testing. This increases testing without affecting relevant clinical endpoints. Also, when a biomarker becomes part of the standardised workup for a certain symptom, primary care centres and emergency telephone services will refer patients to the Emergency Department for testing, even when the pretest probability is low. Katrin contends this bias is not an inherent problem of biomarkers themselves, but of the decision-making process of clinicians. The human brain fears uncertainty. Anything that adds to the feeling of knowing is rewarding, which is the most probable explanation of over testing in settings where medico-legal risks for the clinicians are low. There is an ever-increasing number of patients seeking to rule out serious conditions by relying on biomarker testing to provide certainty. Finally, for more like this, head to our <a href="https://codachange.org/podcasts/" rel="nofollow" target="_blank">podcast page</a>. #CodaPodcast

Biomarkers in Emergency Medicine: Katrin Hruska